Tag: NASDAQ:LPTN

  • Biotech New Lows: Lpath, Inc. (NASDAQ:LPTN), Onconova Therapeutics Inc (NASDAQ:ONTX), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Cleveland BioLabs (NASDAQ:CBLI), Curis, Inc. (NASDAQ:CRIS)

    Lpath, Inc. (NASDAQ:LPTN), net profit margin is -81.30% and weekly performance is -1.79%. On last trading day company shares ended up $3.83. Analysts mean target price for the company is $14.67. Lpath, Inc. (NASDAQ:LPTN), distance from 50-day simple moving average (SMA50) is -11.02%.

    Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price traded down 5.6% during mid-day trading on Tuesday following a dissappointing earnings announcement, Analyst Ratings.Net reports. The stock traded as low as $5.00 and last traded at $5.02, with a volume of 405,465 shares changing hands. The stock had previously closed at $5.32. Onconova Therapeutics Inc (NASDAQ:ONTX), fell 0.23% in last trading session and ended the day on $4.36. ONTX, return on assets is -72.10%. Onconova Therapeutics Inc (NASDAQ:ONTX), quarterly performance is -46.37%.

    On May 21, 2014, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), shares moved up 6.16% in last trading session and was closed at $3.62, while trading in range of $3.31 – 3.65. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), year to date (YTD) performance is -56.59%.

    Cleveland BioLabs, Inc. (NASDAQ:CBLI), ended the last trading day at $0.520. Company weekly volatility is calculated as 6.65% and price to cash ratio as 1.93. Cleveland BioLabs, Inc. (NASDAQ:CBLI), showed a negative weekly performance of 8.77%.

    Curis, Inc. (NASDAQ:CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, announced the appointment of Ali Fattaey, Ph.D. as the Company’s President and Chief Executive Officer and as a member of its Board of Directors. Curis, Inc. (NASDAQ:CRIS), net profit margin is -84.40% and weekly performance is -12.82%. On last trading day company shares ended up $1.70. Analysts mean target price for the company is $5.50. Curis, Inc. (NASDAQ:CRIS), distance from 50-day simple moving average (SMA50) is -24.85%.